Please sign in to follow a disease.
Heart valve fix without a surgeon in the building? new trial aims to prove It's safe
NCT ID NCT07515768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a common heart valve replacement (TAVI) can be performed safely in hospitals that do not have a cardiac surgery team on-site. Currently, TAVI is only done in hospitals with heart surgery backup, which can cause long wait times. The trial will randomly assign 404 patients aged 70 or older with severe aortic stenosis to get TAVI either at a standard hospital or at a pilot center without on-site surgery but with other safety measures in place. The goal is to see if the procedure is just as safe after 30 days, which could help more people get faster treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 404 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
70 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Severe degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient ≥40 mmHg or jet velocity ≥4.0 m/s or an aortic valve area (AVA) of ≤1 cm2 (or AVA index \<0.6 cm2/m2) * Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class ≥ II. * Suitable for percutaneous transfemoral access * Age ≥70 years Exclusion Criteria: * Prior aortic valve replacement * Bicuspid aortic valve on pre-procedural CT * Contraindication to femoral access * Other imaging features indicating increased procedural risk (extremely horizontal aorta, severe aortic root dilatation, aortic annulus outside the range of commercially available devices, high coronary risk occlusion) * Life expectancy \<12 month or active malignancy * Active endocarditis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI turns routine heart tracings into an early warning for a silent valve disease
- Can a new heart valve offer a safer fix for aortic stenosis?
- Can Open-Heart surgery outperform a Tube-Based valve fix?
- Can a new heart valve restore quality of life?
- Does replacing a heart valve clear fluid from the lungs?
- AI ultrasound could unmask silent heart disease in seniors